泰豪肿瘤学、泰豪制药和Cullinan Therapeutics启动针对Zipalertinib的新药申请滚动提交,旨在治疗带有EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌。
泰豪肿瘤学、泰豪制药和Cullinan Therapeutics启动针对Zipalertinib的新药申请滚动提交,旨在治疗带有EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.